<DOC>
	<DOCNO>NCT01245465</DOCNO>
	<brief_summary>In study investigator aim investigate safety possible efficacy Profermin® patient ulcerative colitis . The investigator also aim assess usefulness new online daily symptom registration system .</brief_summary>
	<brief_title>Profermin® Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients eligible 18 50 year age establish diagnosis UC base clinical , endoscopic histological feature . Active disease assess Simple Clinical Colitis Activity Index ( SCCAI ) ( Table 1 ) score 4 12 . Patients initiated treatment azathioprine , 6mercaptopurine , ciclosporin methotrexate within 8 week prior inclusion TNFα inhibitor within 12 week inclusion change UC treatment within 2 week inclusion ineligible study . Concomitant coeliac disease lactose intolerance also exclusion criterion . In addition malignant premalignant condition recent gastroenteritis render patient ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>